Catalyst
Slingshot members are tracking this event:
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 estimated to complete December 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VSTM | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 11, 2018
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02049515?term=Verastem+%26+duvelisib+%26+CLL
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Duvelisib, Ofatumumab, Cll, Ipi-145-07
